What drove the pre-market drop in NWRN.SW stock today?

The pre-market decline reflects short-term profit taking after strong gains (3M +90.80%), elevated volume (**446,742.00**) and overbought technicals (RSI **85.30**). No single negative news item was cited in major outlets today.

What are the key valuation metrics for NWRN.SW stock?

NWRN.SW stock trades at **CHF 26.75** with EPS **1.27** and PE **19.92**. Price/book is high at **342.25**, while free-cash-flow yield is about **4.53%**, reflecting profitable operations but a thin equity base.

How does Meyka AI view NWRN.SW stock near current prices?

Meyka AI rates NWRN.SW with a score of **70.16/100** (Grade B+, suggestion BUY). Meyka AI's forecast model projects **CHF 29.13** monthly, implying about **+8.90%** versus the current **CHF 26.75**. Forecasts are model-based and not guarantees.

What short-term levels should traders watch for NWRN.SW stock?

Watch support at **CHF 24.90** and resistance around **CHF 29.20–31.85**. Reclaiming **CHF 27.50** with volume would indicate stabilized buying; a break below **CHF 24.90** increases downside risk.

CH Stocks

NWRN.SW Newron Pharmaceuticals (SIX) pre-market 16 Jan: -5.42%, earnings watch

ByDanny Kontos January 16, 2026January 16, 2026

The NWRN.SW stock opened weaker in pre-market trade on 16 Jan 2026 after a short profit-taking swing. We see Newron Pharmaceuticals S.p.A. (SIX) at CHF 26.75, down 5.42% intraday from recent highs, with volume at 446,742.00 suggesting heavier selling than the 50-day average. The move follows a sharp multi-month rally (+90.80% over 3 months), leaving momentum indicators overbought and the upcoming earnings date on 24 Mar 2026 in focus.